Abstract: The present disclosure relates to a recombinant gas vesicle nanoparticle, and the recombinant gas vesicle nanoparticle prepared by the method of the present disclosure is a nano-sized protein particle that it is biologically non-toxic and safe. Further, its outer surface protein, GvpC, can be recombined to include the exogenous protein to reconstitute gas vesicle nanoparticles presenting/mounting the exogenous protein on the surface, so that it can be used as various antigen-loaded vaccine compositions that are active under physiological conditions, therapeutic target-specific carriers, including a sensor for target-specific therapy.

Abstract: Described herein are examples of patches which include a hydrogel having an active homeopathic ingredient dissolved therein. The active homeopathic ingredient Berberis vulgaris is dissolved in the hydrogel and is effective at treating molluscum contagiosum. The patches are cured and shaped so that the active ingredient kills the virus over time when the patch is in contact with an infected area. The patches temporarily adhere to the skin and are effective at curing and preventing the spread of viral skin infection, both to other people and to other parts of the infected person's body. The patches may be packaged and sold as an over-the-counter homeopathic product.

Abstract: The present invention falls within the area of polymeric materials based on ultrafine fibres for use in the pharmaceutical, nutraceutical and cosmetic sector, relating to the method of producing self-adhesive patches and the use thereof as a platform for the controlled release of bioactives by means of electrohydrodynamic and/or aerohydrodynamic processing techniques.

Abstract: Neurodegenerative diseases are treated by the co-administration to a subject of an effective amount of a stilbene, a flavonol, and a TLR4/MD2 receptor antagonist. A preferred stilbene is resveratrol, a preferred flavonol is quercetin, and a preferred TLR4/MD2 receptor antagonist is curcumin.

Abstract: Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating dermatological disease, and methods for treating dermatological diseases by administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the skin of a patient in need of treatment.

Abstract: The present disclosure relates to pharmaceutical compositions suitable for inhalation, parenteral administration, and oral administration comprising a an insoluble active ingredient, pharmaceutical systems comprising them, methods of treatment and/or prophylaxis, and uses comprising them.

Abstract: The present disclosure provides compounds and compositions that are useful in treating chronic disorders, including cancer and viral diseases.

Abstract: Methods of treating a subject for a dissociative disorder and methods of screening agents for the ability to modulate dissociative and associative states in a subject are provided. In particular, agents that alter rhythmic neural activity in the posteromedial cortex can be used to modulate dissociative and associative states in a subject.

Abstract: The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.

Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in inducing neuroprotection, in a subject in need thereof. The compound or a pharmaceutically acceptable salt thereof can be used in inducing neuroprotection in a subject suffering from, suspected of suffering from, or considered to be at risk of suffering from a neurodegenerative pathology. The compound or a pharmaceutically acceptable salt thereof also can be used in preventing or treating a neurodegenerative pathology, and/or in preventing or decreasing cognitive impairment in a subject suffering from, suspected of suffering from, or considered to be at risk of suffering from a neurodegenerative pathology.

Abstract: Provided is a medicinal use of fingolimod as sphingomyelinase inhibitor in preventing and treating neurodegenerative diseases caused by sphingolipid disorders. Research has shown that fingolimod can effectively alleviate and significantly improve the motion function of spastic paraplegic mice, enable old paraplegic mice to stand again, and increase the number of times paraplegic mice stand. Meanwhile, the present invention can effectively reduce/lower lipofuscin deposition and axonal myelin sheath tear in mouse brain tissue, can significantly alleviate the reduction or deficiency of sphingomyelin, promote the recycling of sphingomyelin, and correct neurological dysfunction caused by sphingolipid disorders that are due to a sphingomyelin deficiency. Further provided is an application of fingolimod in the preparation of a drug for preventing and treating neurodegenerative diseases caused by sphingolipid disorders.

Abstract: A method for reducing a risk of at least one cardiovascular event in a subject in need thereof, which includes administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the at least one cardiovascular event is chosen from myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death; wherein the subject has no contra-indications to colchicine therapy, and has at least one risk factor; and vii. therapy with at least one drug chosen from aspirin, clopidogrel, statins, beta blockers, calcium blockers, and ACE inhibitors; and wherein the composition reduces the risk of the subject experiencing the at least one cardiovascular event by a greater percentage than a composition that does not include colchicine or the pharmaceutically acceptable salt thereof.

Abstract: A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin.

Abstract: A method for modulating metabolism is provided which includes the step of providing a consumable composition including an extract containing a compound of Formula I to a subject in need thereof thereby modulating the subject's metabolism and addressing the underlying pathogenesis of metabolic disorders, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and type II diabetes mellitus.

Abstract: Described herein are methods for the treatment of an ophthalmic disease or disorder comprising the administration of non-retinoid visual cycle modulators.

Abstract: A composition comprising an active agent that inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT) is provided. With the composition, food intake can be suppressed, and/or body weight can be reduced, and/or metabolic disorders can be prevented and/or treated.

Abstract: A composition comprising an active agent that inhibits acyl-coenzyme A:cholesterol acyltransferase (ACAT) is provided. With the composition, food intake can be suppressed, and/or body weight can be reduced, and/or metabolic disorders can be prevented and/or treated.

Abstract: Disclosed herein are methods of administration of (E)-2-[[3-methoxy-4- (difluoromethoxy)phenyl-l-oxo-2-propenyl]amino]benzoic acid to a subject, involving particular administration regimes for preventing, treating, reducing the severity of and/or reducing the likelihood of reoccurrence of eye conditions such as diabetic retinopathy and proliferative vitreo-retinopathy. Such eye conditions can have serious consequences, including loss of vision and, in some cases blindness.

Abstract: There is provided a composition for use in a therapeutic method of treatment of a subject suffering from a neurological disorder, said composition comprising: A) serine, glycine, betaine, N-acetylglycine, N-acetylserine, dimethylglycine, sarcosine and/or phosphoserine; B)N-acetyl cysteine, cysteine and/or cystine; C) carnitine, deoxycarnitine, gamma-butyrobetaine, 4-trimethylammoniobutanal, 3-hydroxy-N 6,N6,N 6-trimethyl-L-lysine, N6,N6,N6-trimethyl-L-lysine and/or lysine; and D) nicotinamide.

Abstract: The population of Dialister spp. bacteria in the gut microbiome is lower in people with various diseases. We have found that administration of vitamins/vitamin combinations such as: beta-carotene, Vitamin A, Vitamin D, Vitamin B5, Vitamin B2, a combination of Vitamin B2 and Vitamin C, Vitamin K, DHA, or EPA, when administered directly to the large intestine, so that it provides nourishment to the gut microbiome directly, can result in an increase of Dialister spp.

Abstract: Trans-crocetin pharmaceutical compositions including fixed dose liposomal trans-crocetin pharmaceutical compositions, dosing regimens and methods of treating or preventing disorders and conditions associated with, but not limited to, infection, ischemia, hypoxia, ARDS, inflammation, sepsis, shock, stroke, traumatic injury, and proliferative disorders such as cancer are provided. Methods of using fixed dose trans-crocetin pharmaceutical compositions and dosing regimens to treat cardiovascular, renal, liver, inflammatory, metabolic, pulmonary, neurological, and other disorders and conditions are also provided, as are methods of increasing the delivery of oxygen and increasing the efficacy of a therapeutic agent using the provided compositions and dosing regimens.

Abstract: The present invention relates to new stable oral liquid pharmaceutical compositions comprising isotretinoin (13-cis retinoic acid), pharmaceutically accepted salts thereof, or other suitable isotretinoin compounds. The compositions are formulated in a lipid carrier, typically comprising phospholipids, and in embodiments comprising a substantial amount of one or more phosphatidylcholines. Such compositions can further comprise a surfactant component, a medium chain triglyceride component, an antioxidant/preservative component, or combination thereof. The present invention also provides the process of preparation of such compositions and methods of using such compositions in the treatment of various diseases/conditions.

Abstract: Embodiments of the instant disclosure relate to novel compositions and methods for treating a subject having genetic homocystinuria (HCU or other form of genetic homocystinuria). In some embodiments, compositions and methods disclosed herein concern improving efficacy of standard treatments (e.g. trimethylglycine) to reduce dietary compliance requirements and improve outcomes. In accordance with these embodiments, a subject having or suspected of developing classical cystathionine beta-synthase deficient homocystinuria (HCU) or other genetic form of homocystinuria can be treated with a polyamine or diamine or a precursor thereof or a combination thereof for example, in combination with trimethylglycine (e.g. betaine) or other genetic homocystinuria treatment.

Abstract: The present invention relates to a topical pharmaceutical composition comprising a serine protease inhibitor for use in the treatment or prevention of viral infections. The invention is further directed to serine protease inhibitors and a lozenge and a dry nasal preparation comprising the serine protease inhibitor.

Abstract: A stable pharmaceutical composition containing a non-steroidal anti-inflammatory drug derivative, at least comprising a separated solid part and liquid part, the solid part comprising a therapeutically effective dose of non-steroidal anti-inflammatory drug derivative and the liquid part being a pharmaceutically acceptable solvent.

Abstract: A composition for the promotion of alcohol and acetaldehyde degradation in a human is disclosed. The composition, which can be prepared by bringing all the ingredients together in intimate physical admixture, comprises an anti-hangover effective amount of: (a) essential herbs consisting of Ilex paraguarensis (Yerba mate), Eleutherococcus senticosus (Siberian ginseng), Panax ginseng and Zingiberis officinalis (ginger); and (b) one or more electrolyte(s) and, optionally, (c) sulphoraphane. Preferably, the composition is in the form of a low-volume, aqueous, after-alcohol drink, that can avoid some of the potentially adverse effects of previously-known anti-hangover preparations.

Abstract: Compositions and methods for the treatment of COVID-19 in a subject infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The methods may include, among other embodiments, administering to the subject a therapeutically effective amount of a composition or formulation comprising nobiletin or salt, solvate, or prodrug thereof.

Abstract: Disclosed herein are methods of administering resiniferatoxin (RTX) intravesically for treatment of bladder pain, and compositions for use in such methods.

Abstract: The disclosure provides compositions comprising Salvinorin A or a derivative of Salvinorin A for use in treating neurological diseases and conditions.

Abstract: Disclosed here are uses of autophagy inhibitors for treating a subject at risk of suffering from an aneurysm. The present disclosure demonstrates that autophagy plays a role in THSD1-mediated focal adhesion stability and aneurysm formation and characterizes molecular targets for therapeutic intervention.

Abstract: The present invention relates to novel oral film composition comprising anticholinergic agent as active ingredient and pharmaceutically acceptable excipients. The present invention specifically relates to novel oral film composition comprising Glycopyrronium salts as active ingredient and pharmaceutically acceptable excipients. The present invention more specifically relates novel oral film composition comprising Glycopyrronium salts, saliva stimulating agents, film-forming agents, buffering agents, plasticizers and other pharmaceutically acceptable excipients. The present invention more specifically relates to process for the preparation of Glycopyrronium salts oral film comprising the steps of dissolving/mixing, stirring, drying and cutting into film.

Abstract: Methods of treatment, pharmaceutically acceptable solutions, and implantable devices are provided for the intrathecal treatment of AED-resistant seizures using levetiracetam.

Abstract: Provided herein are methods of treating diabetic kidney disease comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, and a SGLT-2 inhibitor to a subject in need thereof.

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

Abstract: The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of opioid use by an opioid use disorder patient; in preventing relapse into opioid use by an opioid use disorder patient; in the promotion of opioid abstinence by an opioid use disorder patient; in the treatment of the symptoms of depression or anxiety associated with opioid use disorder.

Abstract: This disclosure provides methods for inhibiting BAX activity and BAX-mediated apoptosis, as well as methods for treating or preventing BAX-mediated disorders, based, in part, on an unexpected discovery that eltrombopag (EO) can work as as a potent binder to the BAX trigger site and an effective direct BAX inhibitor.

Abstract: A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.

Abstract: Provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a glucokinase-mediated disorder, disease, or condition in a hepatically impaired subject with a glucokinase activator (GKA), for example, dorzagliatin. Also provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a diabetes in a hepatically impaired subject with a GKA. Additionally, provided herein is a method of treating, preventing, or ameliorating one or more symptoms of a chronic liver disease with a GKA.

Abstract: The invention relates to PDE3-inhibitors for use in the treatment of a viral infection. The PDE-3 inhibitors achieve a rapid symptomatic relief in subjects, with the advantage of maintaining antiviral activity.

Abstract: The present invention relates to furazidin for vaginal use in the treatment of a bacterial vaginal infection. Preferably, the bacterial vaginal infection is caused by Gardnerella vaginalis and/or Atopobium vaginae bacteria.

Abstract: The present invention is directed to methods of treating, preventing, and/or ameliorating fibrosis syndrome, and in particular cardiac fibrosis, by administration of a therapeutically effective amount of ifetroban, or a pharmaceutically acceptable salt thereof.

Abstract: A VEGF inhibitor is used in preparation of a medicament for treating hypoxia-related diseases. The VEGF inhibitor can significantly inhibit VEGF stress expression caused by hypoxia by acting on a binding pathway of VEGF and a VEGF receptor, is used for treating hypoxia and other related diseases, can significantly improve the oxygenation index of a patient, and can alleviate the hypoxic state of lung and other organ tissues, having good therapeutic effects.

Abstract: Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR? kinases, and oncogenic forms thereof.

Abstract: The use of P2X4 antagonists for the treatment of dry eye syndrome, more in particular substituted N-phenylacetamide compounds of general formula (I), pharmaceutical compositions and combinations comprising said compounds for use in the treatment or prophylaxis of dry eye syndrome and in particular dry eye, ocular neuropathic pain, ocular trauma and post-operative ocular pain.

Abstract: The present disclosure provides, for example, a composition comprising: 2-(4-cyclopropyl-2-fluoroanilino)-3,4-difluoro-5-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]benzamide or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or salt; and a dispersant (e.g., methylcellulose) and/or a basic compound (e.g., meglumine). According to the present disclosure, there is provided a composition comprising a specific aryl amide derivative that has RAF/MEK complex-stabilizing activity and/or MEK-inhibiting activity and is useful for the treatment or prevention of a cell proliferative disorder, particularly a cancer, the composition having good properties with respect to the dissolution and/or stability of the aryl amide derivative in the composition.

Abstract: Provided herein are pharmaceutical compositions comprising compounds that inhibit Factor XIa or kallikrein and methods of use thereof.

Abstract: CCR2 is involved in the regulation of normal cardiovascular function and during the cardiovascular stress response to hemorrhagic shock and fluid resuscitation. Disclosed herein are methods of using CCR2 inhibitors to reduce fluid requirements and to prevent death from hemodynamic decompensation during resuscitation.

Abstract: The present invention relates to the use of a 2,3,5-substituted thiophene compound for the prevention, amelioration or treatment of gastrointestinal stromal tumor. The 2,3,5-substituted thiophene compound exhibits high inhibitory activity against the growth of gastrointestinal stromal tumor, and thus may be effectively used for the prevention, amelioration or treatment of gastrointestinal stromal tumor.

Abstract: The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

Abstract: The present invention is directed to a topical formulation comprising 1) a dispersed phase comprising: 5 to 15% w/w (percentage weight/weight) nicotinamide; 10 to 60% w/w of a partition coefficient enhancer (Pc enhancer), having a structure of the general formula: CnH2n+2O2 where n represents an integer from 3 to 6 inclusive; and ?10% water and 2) a continuous phase, wherein the formulation has a pH above 4.0. The present invention is also directed to a pharmaceutical composition comprising the topical formulation according to the invention, a pharmaceutical composition according to the invention for use in therapy, and the use of the topical formulation as a cosmetic agent.